CL2015000078A1 - Composicion de silicato de zirconio microporoso, con un tamaño de particula mayor a 3 micrones y menos de un 7% menor que 3 micrones, con sodio menos al 12% en peso y cationes divalentes de 1-100ppm; y su uso para el tratamiento de hipercalemia en pacientes hipercalemicos - Google Patents

Composicion de silicato de zirconio microporoso, con un tamaño de particula mayor a 3 micrones y menos de un 7% menor que 3 micrones, con sodio menos al 12% en peso y cationes divalentes de 1-100ppm; y su uso para el tratamiento de hipercalemia en pacientes hipercalemicos

Info

Publication number
CL2015000078A1
CL2015000078A1 CL2015000078A CL2015000078A CL2015000078A1 CL 2015000078 A1 CL2015000078 A1 CL 2015000078A1 CL 2015000078 A CL2015000078 A CL 2015000078A CL 2015000078 A CL2015000078 A CL 2015000078A CL 2015000078 A1 CL2015000078 A1 CL 2015000078A1
Authority
CL
Chile
Prior art keywords
less
microns
100ppm
treatment
composition
Prior art date
Application number
CL2015000078A
Other languages
English (en)
Spanish (es)
Inventor
Donald Jeffrey Keyser
Alvaro F Guillem
Original Assignee
Zs Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zs Pharma Inc filed Critical Zs Pharma Inc
Publication of CL2015000078A1 publication Critical patent/CL2015000078A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0006—Controlling or regulating processes
    • B01J19/0013—Controlling the temperature of the process
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0053—Details of the reactor
    • B01J19/006—Baffles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0053—Details of the reactor
    • B01J19/0066—Stirrers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/18—Stationary reactors having moving elements inside
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/02—Processes using inorganic exchangers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/14—Base exchange silicates, e.g. zeolites
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/025—Silicon compounds without C-silicon linkages
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00049—Controlling or regulating processes
    • B01J2219/00051—Controlling the temperature
    • B01J2219/00054—Controlling or regulating the heat exchange system
    • B01J2219/00056—Controlling or regulating the heat exchange system involving measured parameters
    • B01J2219/00058—Temperature measurement
    • B01J2219/00063—Temperature measurement of the reactants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00049—Controlling or regulating processes
    • B01J2219/00051—Controlling the temperature
    • B01J2219/00074—Controlling the temperature by indirect heating or cooling employing heat exchange fluids
    • B01J2219/00087—Controlling the temperature by indirect heating or cooling employing heat exchange fluids with heat exchange elements outside the reactor
    • B01J2219/00094—Jackets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00761—Details of the reactor
    • B01J2219/00763—Baffles
    • B01J2219/00765—Baffles attached to the reactor wall
    • B01J2219/00768—Baffles attached to the reactor wall vertical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Geology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
CL2015000078A 2012-07-11 2015-01-12 Composicion de silicato de zirconio microporoso, con un tamaño de particula mayor a 3 micrones y menos de un 7% menor que 3 micrones, con sodio menos al 12% en peso y cationes divalentes de 1-100ppm; y su uso para el tratamiento de hipercalemia en pacientes hipercalemicos CL2015000078A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261670415P 2012-07-11 2012-07-11
US201361800291P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015000078A1 true CL2015000078A1 (es) 2015-06-05

Family

ID=49916686

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015000078A CL2015000078A1 (es) 2012-07-11 2015-01-12 Composicion de silicato de zirconio microporoso, con un tamaño de particula mayor a 3 micrones y menos de un 7% menor que 3 micrones, con sodio menos al 12% en peso y cationes divalentes de 1-100ppm; y su uso para el tratamiento de hipercalemia en pacientes hipercalemicos

Country Status (16)

Country Link
US (1) US9707255B2 (forum.php)
EP (1) EP2872148A4 (forum.php)
JP (1) JP2015529640A (forum.php)
KR (1) KR20150036555A (forum.php)
CN (1) CN104968336A (forum.php)
AU (1) AU2013290141A1 (forum.php)
BR (1) BR112015000636A2 (forum.php)
CA (1) CA2878832A1 (forum.php)
CL (1) CL2015000078A1 (forum.php)
CO (1) CO7200258A2 (forum.php)
HK (2) HK1209029A1 (forum.php)
IL (1) IL236655A0 (forum.php)
IN (1) IN2015KN00201A (forum.php)
MX (1) MX2015000381A (forum.php)
PH (1) PH12015500071A1 (forum.php)
WO (1) WO2014011876A2 (forum.php)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6071906B2 (ja) * 2011-02-11 2017-02-01 ズィーエス・ファーマ，インコーポレーテッド 高カリウム血症の処置のための微孔質ジルコニウムケイ酸塩
JP2015529640A (ja) 2012-07-11 2015-10-08 ズィーエス・ファーマ，インコーポレーテッド 高カルシウム血症患者における高カリウム血症の治療のための微多孔性ケイ酸ジルコニウム、および高カリウム血症の治療のための改善されたカルシウム含有組成物
WO2014165670A1 (en) 2013-04-05 2014-10-09 ZS Pharma, Inc. Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
KR102332954B1 (ko) * 2013-11-08 2021-11-29 제트에스 파마, 인코포레이티드 고칼륨혈증의 치료를 위한 미세다공성 규산지르코늄
US20160038538A1 (en) * 2013-11-08 2016-02-11 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
US11577014B2 (en) 2019-07-09 2023-02-14 Uop Llc Process for removing strontium ions from bodily fluids using metallate ion exchange compositions
US11964266B2 (en) 2019-07-09 2024-04-23 Uop Llc Process for removing cobalt, lead, cadmium and chromium ions from bodily fluids using metallate ion exchange compositions
US11484875B2 (en) 2019-07-09 2022-11-01 Uop Llc Process for removing mercury ions from bodily fluids using titanium metallate ion exchange compositions
TWI732489B (zh) * 2020-03-17 2021-07-01 國防醫學院 應用心電圖快速偵測鉀離子異常之方法及其系統
US12036528B2 (en) 2020-09-30 2024-07-16 Uop Llc Process for removing lead ions from boldily fluids using metallate ion exchange compositions
CN119643609A (zh) * 2025-02-17 2025-03-18 北京华睿鼎信科技有限公司 一种晶相杂质的分析方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3329480A (en) 1963-10-18 1967-07-04 Union Oil Co Crystalline zircono-silicate zeolites
US3947279A (en) 1971-12-23 1976-03-30 Owens-Illinois, Inc. Thermally crystallizable glasses possessing precision controlled crystallization and flow properties and process of producing same
US3959445A (en) * 1973-04-30 1976-05-25 E. I. Du Pont De Nemours And Company Highly absorbent, low bulk density sodium silicate
US4581141A (en) * 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
FR2444005A1 (fr) * 1978-12-15 1980-07-11 Ugine Kuhlmann Procede industriel de fabrication en semi-continu de zeolithe a
LU84743A1 (fr) * 1983-04-11 1984-11-28 Sipac Procede de fabrication de zeolite a et produits obtenus
US4943545A (en) * 1987-06-08 1990-07-24 Mobil Oil Corporation Activation of zeolites
US5032556A (en) 1989-02-21 1991-07-16 Tosoh Corporation Preparation method for zircon powder
US5015453A (en) 1989-04-28 1991-05-14 W. R. Grace & Co.-Conn. Crystalline group IVA metal-containing molecular sieve compositions
JP3265344B2 (ja) 1990-03-16 2002-03-11 東ソー株式会社 ジルコン粉末の合成法
US5338527A (en) 1992-08-20 1994-08-16 Uop Zirconium silicate composition, method of preparation and uses thereof
BR9307330A (pt) 1992-10-28 1999-06-01 Crosfield Joseph & Sons Sílica amorfa processo para sua fabricação e composição de pasta de dentes
US5518707A (en) 1994-10-24 1996-05-21 Uop Metallo germanates
GB9601398D0 (en) 1996-01-24 1996-03-27 Piper Edwina M Composition
IT1283284B1 (it) 1996-03-21 1998-04-16 Eniricerche Spa Zeolite ers-10 e procedimento per la sua preparazione
FR2750893B1 (fr) 1996-07-12 1998-10-30 Elf Aquitaine Procede de synthese de zeolithe avec agitation homogene du milieu, dispositif et application
CA2214495C (en) 1996-09-25 2002-02-05 Daniel L. Woodard Hydrated zirconium silicate composition for purification of nucleic acids
US5888472A (en) * 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
US5891417A (en) 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
EP0982785A4 (en) * 1997-05-12 2001-04-18 Japan Represented By Director SEPARATOR FOR ACCUMULATOR AND ALKALI ELECTRIC ACCUMULATOR USING THE SAME
JPH11292769A (ja) * 1998-04-10 1999-10-26 Toyo Seiyaku Kasei Kk 高カリウム血症改善剤組成物
US6007790A (en) 1998-08-13 1999-12-28 Uop Llc Family of microporous indium silicate compositions
US5989518A (en) * 1998-12-29 1999-11-23 Uop Llc Process for synthesizing and controlling the particle size and particle size distribution of a molecular sieve
EP1038580B1 (en) 1999-03-26 2005-05-25 Uop Llc Ammonium ion adsorption process using zirconium silicate and zirconium germanate molecular sieves
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US6332985B1 (en) * 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US7041274B2 (en) 1999-10-22 2006-05-09 Intevep, S.A. Aluminosilicate compositions, preparation and use
US6379641B1 (en) 2000-05-01 2002-04-30 Uop Llc Microporous rare earth silicates and method of producing same
US6596254B1 (en) 2000-06-12 2003-07-22 Sandia Corporation Niobate-based octahedral molecular sieves
US20040105895A1 (en) 2001-02-06 2004-06-03 Ash Stephen R Monovalent-selective cation exchangers as oral sorbent therapy
US6579460B1 (en) 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
US6814871B1 (en) * 2001-07-13 2004-11-09 Uop Llc Process for removing pollutants from aqueous streams
JP2004149525A (ja) * 2002-10-09 2004-05-27 Sekisui Chem Co Ltd カリウムイオン吸着剤及びその製造方法、並びに高カリウム血症治療剤
US6689335B1 (en) 2002-12-19 2004-02-10 Eastman Kodak Company Silver ion sequester and release agent
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
CN1894029B (zh) 2003-12-15 2011-05-11 旭化成化学株式会社 多孔成形物及其生产方法
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
GB2430624B (en) * 2004-03-30 2009-08-05 Ilypsa Inc Ion binding compositions
US7566432B2 (en) 2004-12-28 2009-07-28 Renal Solutions, Inc. Method of synthesizing zirconium phosphate particles
WO2006134915A1 (ja) 2005-06-14 2006-12-21 Asahi Kasei Chemicals Corporation 水処理装置及び水処理方法
US8617609B2 (en) 2005-09-30 2013-12-31 Relypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
US8586097B2 (en) * 2005-09-30 2013-11-19 Relypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007127390A2 (en) 2006-04-28 2007-11-08 Biolife, L.L.C. Materials and methods for wound treatment
WO2008070072A2 (en) 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
KR101002571B1 (ko) 2007-01-03 2010-12-17 주식회사 인실리코텍 다공성 금속-유기 골격 구조를 갖는 배위중합체 결정 및이의 제조방법
ES2304890B1 (es) 2007-04-03 2009-10-30 Universidad De Zaragoza Procedimiento de obtencion de esferas de titanosilicato.
DE202009018732U1 (de) 2008-02-26 2012-11-27 Corning Inc. Läutermittel für Silikatgläser
US20100104527A1 (en) 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US8865121B2 (en) 2009-06-18 2014-10-21 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material
US20120070468A1 (en) 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
JP6071906B2 (ja) 2011-02-11 2017-02-01 ズィーエス・ファーマ，インコーポレーテッド 高カリウム血症の処置のための微孔質ジルコニウムケイ酸塩
JP5982469B2 (ja) 2011-04-08 2016-08-31 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ アシル化触媒の製造方法
US10092688B2 (en) 2011-05-13 2018-10-09 Laura Jean Robinson Medicament kit and method of use
US9527751B2 (en) 2011-11-11 2016-12-27 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material of the CHA-type structure
EP2812281B1 (en) 2012-02-06 2020-07-29 Basf Se Iron- and copper-containing zeolite beta from organotemplate-free synthesis and use thereof in the selective catalytic reduction of nox
US9475041B2 (en) 2012-04-24 2016-10-25 Basf Se Zeolitic materials and methods for their preparation using alkenyltrialkylammonium compounds
JP2015529640A (ja) 2012-07-11 2015-10-08 ズィーエス・ファーマ，インコーポレーテッド 高カルシウム血症患者における高カリウム血症の治療のための微多孔性ケイ酸ジルコニウム、および高カリウム血症の治療のための改善されたカルシウム含有組成物
BR112015008962B1 (pt) 2012-10-22 2021-09-21 Zs Pharma, Inc Composição de silicato de zircônio para o tratamento de hipercalemia

Also Published As

Publication number Publication date
IL236655A0 (en) 2015-02-26
WO2014011876A2 (en) 2014-01-16
CA2878832A1 (en) 2014-01-16
CO7200258A2 (es) 2015-02-27
JP2015529640A (ja) 2015-10-08
HK1215861A1 (zh) 2016-09-23
KR20150036555A (ko) 2015-04-07
EP2872148A2 (en) 2015-05-20
HK1209029A1 (en) 2016-03-24
EP2872148A4 (en) 2016-06-15
CN104968336A (zh) 2015-10-07
WO2014011876A3 (en) 2015-07-16
IN2015KN00201A (forum.php) 2015-06-12
PH12015500071A1 (en) 2015-03-16
US20140105971A1 (en) 2014-04-17
BR112015000636A2 (pt) 2017-08-08
MX2015000381A (es) 2015-11-23
US9707255B2 (en) 2017-07-18
AU2013290141A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
CL2015000078A1 (es) Composicion de silicato de zirconio microporoso, con un tamaño de particula mayor a 3 micrones y menos de un 7% menor que 3 micrones, con sodio menos al 12% en peso y cationes divalentes de 1-100ppm; y su uso para el tratamiento de hipercalemia en pacientes hipercalemicos
IL289016A (en) Methods and medical preparation for the treatment and prevention of cardiomyopathy resulting from energy failure
CL2016001166A1 (es) Silicato de zirconio microporoso para el tratamiento de la hipercalemia
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
CY2018022I2 (el) Πολυκυκλικες ενωσεις καρβαμοϋλπυριδονης και φαρμακευτικη χρηση αυτων
BR112013029269A8 (pt) combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2
PT2892808T (pt) Agregados estabilizados e outros materiais e estruturas para fins que incluem absorção de energia mas que não estão limitados à mesma
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
BR112015022782A2 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
SG11201600821SA (en) Waste incinerator ash as aerating agent for the manufacture of lightweight construction materials
DOP2014000160A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
PH12016500284A1 (en) Oral care composition
CR20140513A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
JO3154B1 (ar) عوامل مضادة لـ trpv4
CL2014001047A1 (es) Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.
BR112014020992A2 (pt) Composto,uso de composto na fabricação de um medicamento e composição farmacêutica
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
CL2013002565A1 (es) Composición granular dispersable en agua, que comprende en peso y respecto del total de la composición: a) entre 30-85% de azufre; b) entre 8-60% de sulfato de zinc monohidratado y c) un excipiente agroquímicamente aceptable, y donde los fránulos dispersables en agua comprende partículas entre 0,2 a 50 micrones.
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
EP3741360C0 (en) PHARMACEUTICAL COMPOSITION COMPRISING PHOSPHATE BINDER PARTICLES
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
BR112017010218A2 (pt) placa de gesso.
EP2666482A4 (en) PARTICLE COMPOSITION AND PHARMACEUTICAL COMPOSITION WITH PARTICLE COMPOSITION
BR112014033013A2 (pt) uso de tiossulfato para potenciar o efeito anti-patogênico de lactobacillus